Literature DB >> 35681057

Tailoring treatment in metastatic renal cell carcinoma.

Eduard Roussel1, Benoit Beuselinck2, Maarten Albersen3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35681057     DOI： 10.1038/s41585-022-00615-z

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   16.430


× No keyword cloud information.
  2 in total

1.  Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.

Authors:  Yann-Alexandre Vano; Réza Elaidi; Letuan Phan; Wolf Herman Fridman; Catherine Sautès-Fridman; Stéphane Oudard
Journal:  Lancet Oncol       Date:  2022-07       Impact factor: 54.433

2.  Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.

Authors:  Eduard Roussel; Annelies Verbiest; Lisa Kinget; Bram Boeckx; Jessica Zucman-Rossi; Gabrielle Couchy; Stefano Caruso; Sylvie Job; Aurélien de Reyniès; Liesbeth De Wever; Marcella Baldewijns; Hendrik Van Poppel; Steven Joniau; Diether Lambrechts; Maarten Albersen; Benoit Beuselinck
Journal:  Clin Genitourin Cancer       Date:  2021-07-10       Impact factor: 2.872
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.